Lead sponsor
Eli Lilly and Company
231 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
231
Trials led
61
Active
151,427
Total enrollment
4,739
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
92
Phase 1/2
1
Phase 2
27
Phase 2/3
1
Phase 3
96
Phase 4
13
Not applicable
1
Trials by status
Not yet recruiting
2
Recruiting
28
Active, not recruiting
31
Completed
166
Terminated
2
Withdrawn
1
Unknown
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)BMI ≥27 · Established ASCVD/CKDPh 3Active, not recruiting10,000
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)Established ASCVD/CKDPh 3Recruiting7,140
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)—Ph 3Recruiting4,500
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)BMI 30-34.9Ph 4Recruiting3,000
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight—Ph 2Recruiting1,481
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)BMI ≥25Ph 3Active, not recruiting1,250
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on MetforminBMI 25-40Ph 2/3Completed1,202
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes—Ph 3Active, not recruiting1,200
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)BMI ≥25Ph 3Active, not recruiting974
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)BMI ≥23Ph 3Completed917
A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 DiabetesBMI ≥23Ph 2Completed755
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialBMI ≥30Ph 3Completed731
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityBMI ≥30Ph 3Active, not recruiting600
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesBMI ≥25Ph 3Active, not recruiting600
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)BMI ≥23Ph 3Completed537
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightBMI 27-40Ph 1Completed533
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or ObeseBMI ≥30Ph 2Completed507
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes MellitusHbA1c 7-10%Ph 3Completed492
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1—Ph 3Active, not recruiting487
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2—Ph 3Active, not recruiting487
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 DiabetesBMI ≥23Ph 3Completed443
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesBMI ≥30Ph 3Completed441
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and ObesityBMI ≥35Ph 2Active, not recruiting414
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight—Ph 2Not yet recruiting400
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes MellitusBMI 18.5-35Ph 3Completed394
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityBMI ≥30Ph 2Completed392
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes MellitusBMI 18.5-35Ph 3Completed361
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesBMI ≥27Ph 2Active, not recruiting350
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or ObesityBMI ≥23Ph 4Recruiting344
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and ExenatideHbA1c ≥7%Ph 3Completed339
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)BMI ≥23Ph 3Active, not recruiting320
A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin MonotherapyBMI ≥25Ph 2Completed318
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes MellitusBMI 23-50Ph 2Completed318
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)Age 12-17Ph 3Recruiting300
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder—Ph 2Active, not recruiting300
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related ComorbiditiesBMI ≥30Ph 2Completed272
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightBMI ≥27Ph 2Completed263
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight—Ph 2Active, not recruiting252
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideBMI ≥27Ph 2Recruiting240
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in IndiaBMI ≥23Ph 4Completed212
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)BMI ≥23Ph 3Completed206
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesHbA1c 7.5-10.5%Ph 2Recruiting200
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityBMI 27-40Ph 1Completed188
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightBMI ≥27Ph 2Completed179
Effects of LY2189265 on Glycemic Control in Participants With Type 2 DiabetesBMI 23-40Ph 2Completed167
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)BMI ≥25Ph 4Completed152
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesAge 12-17Ph 3Recruiting150
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesHbA1c ≤9%Ph 3Active, not recruiting150
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesBMI ≥27Ph 2Completed146
A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)BMI ≥18.5Ph 1Completed142
A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy ParticipantsBMI 22-30Ph 1Completed125
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight—Ph 1Completed120
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)BMI 25-45Ph 1Completed117
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus—Ph 1Recruiting95
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 DiabetesBMI 27-45Ph 1Completed94
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy ParticipantsBMI 23-35Ph 1Completed86
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943BMI ≥30Ph 1Completed85
A Study of LY3325656 in Healthy Participants and Participants With Type 2 DiabetesBMI ≥18.5Ph 1Completed80
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaBMI 25-45Ph 1Active, not recruiting78
A Study of LY3457263 in Healthy Participants and Participants With Type 2 DiabetesBMI 18.5-35Ph 1Completed67
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection DevicesBMI 18.5-30Ph 1Completed65
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)BMI 23-35Ph 1Completed64
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes MellitusHbA1c 7-10%Ph 1Completed62
A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 DiabetesBMI 23-45Ph 1/2Terminated60
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection DevicesBMI 18.5-32Ph 1Completed57
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)Age 10-17Ph 3Recruiting55
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using TirzepatideBMI 30-45Ph 1Completed55
A Study of Tirzepatide at Different Injection Sites in Participants With Different Body SizesBMI 18.5-45Ph 1Completed54
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese ParticipantsHealthy volunteersPh 1Completed52
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsBMI ≥27Ph 1Completed50
A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual SyringeBMI 18.5-32Ph 1Completed50
A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 DiabetesBMI 20-35Ph 1Completed48
A Study of Tirzepatide Administered by Two Different Devices in Healthy ParticipantsBMI 18-32Ph 1Completed47
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseBMI 27-40Ph 1Completed46
A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney FunctionBMI 19-40Ph 1Completed45
A Safety Study of LY3437943 Given as a Single Injection in Healthy ParticipantsBMI 19-40Ph 1Completed45
A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionBMI 19-42Ph 1Completed43
A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus—Ph 1Active, not recruiting40
A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female ParticipantsBMI ≥18.5Ph 1Completed40
A Study of Two Different Formulations of LY3502970 in Healthy ParticipantsBMI 18.5-35Ph 1Completed39
A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes MellitusBMI 18.5-40Ph 1Completed38
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.BMI 19-40Ph 1Recruiting36
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using TirzepatideBMI 27-45Ph 1Completed36
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy ParticipantsBMI 18.5-35Ph 1Completed32
A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.BMI 23-35Ph 1Completed30
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or OverweightBMI 27-40Ph 1Completed30
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy ParticipantsBMI 18.5-35Ph 1Completed30
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsBMI 22-35Ph 1Completed30
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionBMI 19-40Ph 1Completed29
A Study of LY3502970 in Participants With Impaired and Normal Liver FunctionBMI 18.5-40Ph 1Completed29
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionBMI 19-40Ph 1Recruiting28
A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy ParticipantsBMI 18.5-32Ph 1Completed28
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy ParticipantsBMI 18.5-35Ph 1Completed27
A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) ImpairmentBMI 19-40Ph 1Completed26
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy ParticipantsBMI 18.5-35Ph 1Completed26
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.BMI 18.5-42Ph 1Completed24
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related ComorbiditiesBMI ≥30Ph 1Completed24
A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy ParticipantsBMI 18.5-32Ph 1Completed24
A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female ParticipantsBMI 18.5-30Ph 1Completed22